Spatially Fractionated Radiation Therapy for Cancer

This trial tests whether spatially fractionated radiation therapy (SFRT) can ease symptoms such as pain, trouble breathing, bleeding, or swallowing difficulties in individuals with inoperable solid tumors. SFRT delivers uneven radiation doses to the tumor, potentially protecting healthy tissue, while the standard method, external beam radiation therapy (EBRT), targets cancer from outside the body. Participants will receive either the standard EBRT alone or both the new SFRT and standard EBRT to determine which approach is more effective. The trial seeks individuals with solid tumors larger than 5 cm who are not surgical candidates and experience significant symptoms like pain or difficulty breathing. As an unphased trial, this study provides a unique opportunity to explore innovative treatment options that might improve quality of life.

The trial does not specify whether you need to stop taking your current medications. However, it does allow concurrent systemic therapy (like chemotherapy or immunotherapy) during radiation treatment, so you might be able to continue some treatments. It's best to discuss your specific medications with the trial team.

Research has shown that spatially fractionated radiation therapy (SFRT) is generally safe and well-tolerated. Studies have found that patients experience few side effects with this treatment. For example, one study noted that SFRT led to a significant reduction in tumor size with only minor side effects. Another report found that about 90% of patients experienced quick and substantial improvements with excellent tolerance to the treatment.

Researchers are excited about Spatially Fractionated Radiation Therapy (SFRT) because it offers a novel approach to treating cancer that differs from traditional methods. SFRT involves delivering high doses of radiation to small, focused areas of the tumor, potentially sparing surrounding healthy tissue more effectively than conventional radiation therapy. This technique could enhance the effectiveness of palliative care by providing immediate relief and possibly improving overall outcomes for patients. Unlike standard External Beam Radiation Therapy (EBRT), which is applied uniformly, SFRT's precision may lead to fewer side effects and a better quality of life for patients during treatment.

Research has shown that spatially fractionated radiation therapy (SFRT) can effectively treat large tumors. In one study, 84.2% of patients responded positively, with some tumors partially shrinking. Other studies have reported response rates between 78% and 91%, with some tumors disappearing completely. This method uses a grid pattern to focus high doses of radiation on specific tumor parts, potentially protecting nearby healthy tissue. In this trial, participants in Group I will receive a single fraction of SFRT followed by standard palliative external beam radiation therapy (EBRT), while Group II will receive only standard palliative EBRT. Early results suggest that SFRT not only effectively shrinks tumors but also reduces symptoms like pain and breathing problems.¹²³⁶⁷